Stage 3 Mesothelioma in 2026: 5 Treatment Paths, Survival Data, and What Your Diagnosis Means

What Are the Key Facts About Stage 3 Mesothelioma?

• Staging definition: Stage III pleural mesothelioma is defined by the AJCC 8th Edition as T3 N0-1 M0 or T1-3 N2 M0 — meaning the tumor has grown into nearby structures or spread to regional lymph nodes but has not metastasized to distant organs [8].
• Median overall survival for stage III pleural mesothelioma ranges from 15.5 months with chemotherapy alone to 18.9 months with surgery-based multimodal therapy, based on National Cancer Database analysis of 13,731 patients [1].
• Cell type is the strongest prognostic variable: Epithelioid stage III pleural mesothelioma patients treated with surgery have a median survival of approximately 22 months, while sarcomatoid patients across all treatments survive approximately 6 to 8 months [1][9].
• Immunotherapy has changed the landscape: CheckMate 743 5-year data show nivolumab plus ipilimumab achieves 14% 5-year overall survival versus 6% with chemotherapy (HR 0.74) [2].
• Non-epithelioid patients benefit most from immunotherapy: 12% 5-year survival with nivolumab/ipilimumab versus 1% with chemotherapy (HR 0.48) [2].
• Surgery eligibility is narrowing: The 2025 ASCO guideline recommends surgery only for patients with T1-3 N0 epithelioid disease [4], meaning many stage III patients with N1-2 involvement are directed toward systemic therapy.
• Lung-sparing surgery is preferred: Pleurectomy/decortication (PD) is associated with 7.01 months longer survival than extrapleural pneumonectomy (EPP), per a 2025 meta-analysis [11].
• The MARS 2 trial challenged surgery: Extended pleurectomy/decortication plus chemotherapy showed 19.3 months median OS versus 24.8 months for chemotherapy alone, raising questions about surgical benefit in certain populations [6].
• Conditional survival offers hope: Patients who survive 2 years past their diagnosis gain 5 to 8 additional years of life expectancy, meaning the initial statistics become less relevant over time.
• Real-world outcomes lag trial data: Patients treated outside of clinical trials typically experience survival 3 to 5 months shorter than published trial outcomes [13].
• SEER regional-stage data: 1-year overall survival is 40%, 2-year is 17%, and 5-year is 4% for regional-stage (approximately stage II-III) pleural mesothelioma [10].
• Treatment at specialized centers matters: The IASLC analysis found stage III-IV disease carries an HR of 1.49 versus stage I-II, but outcomes improve significantly at high-volume mesothelioma treatment centers [9].

What Does a Stage 3 Diagnosis Actually Mean for Your Body?

Stage 3 pleural mesothelioma means the cancer has moved beyond the pleural lining where it started but has not spread to distant organs. The AJCC 8th Edition staging system divides stage III into two scenarios [8]: the tumor has grown into nearby structures such as the chest wall, diaphragm, or mediastinum (T3 with N0-1 nodes), or the tumor may be smaller but cancer cells have reached the N2 lymph nodes on the same side of the chest (T1-3 N2 M0).

Understanding this distinction matters because it determines your treatment options. A patient with a T3 tumor but N0 lymph nodes may still be a candidate for surgery. A patient with N2 lymph node involvement is more likely to be directed toward systemic therapy, regardless of tumor size [4]. If you are unclear about your substaging, review our guide to understanding mesothelioma diagnosis for a detailed breakdown.

"The most important question when you hear 'stage 3' is not how long you have — it is whether your specific staging allows you to access all five treatment pathways. I have seen patients reclassified from stage 3B to 3A after a second opinion at a specialized center, and that reclassification opened the door to surgery and an entirely different trajectory."

— David Foster, Director of Client Services, Danziger & De Llano

Physically, most stage 3 patients experience persistent chest pain, increasing shortness of breath, fatigue, and sometimes unexplained weight loss. Pleural effusion — fluid buildup between the lung and chest wall — is common and often requires periodic drainage. These symptoms are manageable with palliative care alongside curative-intent treatment, and symptom management should begin immediately, not as a last resort [13].

What Is the Survival Data for Stage 3 Pleural Mesothelioma by Treatment Type?

Survival varies dramatically based on the treatment approach. Here is the most current data, broken down by modality:

Surgery-based multimodal therapy: The 2023 National Cancer Database analysis found stage III pleural mesothelioma patients treated with surgery had a median overall survival of 18.9 months. For epithelioid histology specifically, median survival with surgery reached approximately 22 months [1]. However, the 2025 ASCO guideline now restricts surgical recommendations to T1-3 N0 epithelioid patients only [4], meaning fewer stage III patients will qualify going forward.

Immunotherapy (nivolumab + ipilimumab): The CheckMate 743 5-year update, published in the Journal of Clinical Oncology in February 2026, showed 14% overall survival at 5 years versus 6% with chemotherapy (HR 0.74, 95% CI 0.62-0.88) [2]. For non-epithelioid patients, the results are even more striking: 12% 5-year survival with immunotherapy versus just 1% with chemotherapy (HR 0.48) [2]. These are all-comers data (not stage III-specific), but they represent the strongest long-term survival signal in the disease.

Chemotherapy alone: The NCDB analysis showed stage III chemotherapy-only patients had a median survival of 15.5 months [1]. Standard first-line chemotherapy is pemetrexed plus cisplatin or carboplatin.

Chemotherapy + pembrolizumab: The IND.227 trial combining pembrolizumab with chemotherapy showed median OS of 17.3 months versus 16.1 months for chemotherapy alone (HR 0.79), with a 52% objective response rate [3]. This combination offers a higher tumor shrinkage rate than either modality alone.

Chemotherapy alone (MARS 2 context): The MARS 2 trial found that extended pleurectomy/decortication plus chemotherapy produced 19.3 months median OS compared to 24.8 months for chemotherapy alone [6]. While controversial, this trial raised the possibility that surgery may not benefit all stage III patients and shifted clinical thinking toward more careful patient selection.

"The survival numbers can feel overwhelming, but the takeaway is this: there is no single survival number for stage 3 mesothelioma. Your cell type, your treatment center, whether you qualify for surgery or immunotherapy — these variables create a range, not a fixed outcome. A non-epithelioid patient on immunotherapy has an entirely different trajectory than a non-epithelioid patient on chemotherapy alone."

— David Foster, Director of Client Services, Danziger & De Llano

What Are the 5 Treatment Paths Available in 2026?

Stage 3 pleural mesothelioma patients in 2026 have more options than at any point in this disease's history. The five primary pathways are:

Path 1: Surgery-Based Multimodal Therapy

Who qualifies: T1-3 N0 epithelioid patients with adequate cardiopulmonary reserve, per the 2025 ASCO guideline [4]. This is a narrower group than in previous years.

What it involves: Pleurectomy/decortication (PD) is now preferred over extrapleural pneumonectomy (EPP). A 2025 meta-analysis found PD associated with 7.01 months longer survival than EPP [11]. Surgery is combined with chemotherapy (neoadjuvant, adjuvant, or both) and potentially immunotherapy.

Expected survival: Median OS approximately 18.9 to 22 months for stage III epithelioid patients [1]. Perioperative nivolumab with or without ipilimumab (Arm B) has shown a median OS of 28.6 months in early data [7].

Path 2: First-Line Immunotherapy

Who qualifies: All histological subtypes, including non-epithelioid patients who are the strongest beneficiaries. Particularly favored for sarcomatoid and biphasic histology.

What it involves: Nivolumab (240 mg every 2 weeks) plus ipilimumab (1 mg/kg every 6 weeks) is the standard regimen, continued until progression or unacceptable toxicity.

Expected survival: 5-year OS of 14% overall, 12% for non-epithelioid (versus 1% with chemotherapy) [2]. For non-epithelioid stage III patients, this is the single most impactful treatment advance in mesothelioma history.

Path 3: Chemotherapy Plus Immunotherapy

Who qualifies: Patients seeking both tumor shrinkage (higher ORR) and immune system activation. Often considered for epithelioid patients where the nivo/ipi survival advantage is less pronounced than in non-epithelioid disease.

What it involves: Pembrolizumab added to platinum-based chemotherapy (pemetrexed + cisplatin or carboplatin), based on the IND.227 regimen [3].

Expected survival: Median OS 17.3 months, ORR 52% [3]. The higher response rate may be particularly relevant for patients who need rapid tumor burden reduction.

Path 4: Chemotherapy Alone

Who qualifies: Patients who cannot tolerate immunotherapy, have contraindications to checkpoint inhibitors (autoimmune disease, organ transplant recipients), or are in regions where immunotherapy access is limited.

What it involves: Pemetrexed plus cisplatin or carboplatin, typically 4 to 6 cycles, with maintenance pemetrexed in some protocols.

Expected survival: Median OS 15.5 months for stage III [1]. This remains the baseline against which all other approaches are measured.

Path 5: Clinical Trials

Who qualifies: Eligibility varies by trial. Many current trials accept previously treated patients. Stage III disease is eligible for most ongoing studies.

Key trials in 2026:

• eVOLVE-Meso (NCT06097728): Phase III trial testing volrustomig, a bispecific antibody targeting PD-1 and CTLA-4 simultaneously, enrolling 825 patients. This is the largest mesothelioma trial in history.
• CAR-T cell therapy: 5 trials are currently open. Memorial Sloan Kettering has reported a 72% objective response rate with an intrapleural delivery approach targeting mesothelin.
• Pegargiminase (ATOMIC-Meso): Already completed Phase III, showing OS of 9.3 versus 7.7 months in non-epithelioid pleural mesothelioma (HR 0.71) [5]. Access may be available through expanded access programs.
• TTFields: The STELLAR Phase II trial showed median OS of 18.2 months when combined with chemotherapy [12], and further studies are ongoing.

For a comprehensive guide to trial eligibility and enrollment, see our clinical trials eligibility and enrollment guide. You can also review mesothelioma treatment centers that run active clinical programs.

How Does Cell Type Change the Prognosis?

Cell type — also called histology — is arguably the single most important prognostic variable in stage 3 pleural mesothelioma, even more predictive than substage in many analyses [9].

Epithelioid (60-80% of cases): This subtype responds best to both surgery and chemotherapy. Stage III epithelioid patients who undergo surgery have a median survival of approximately 22 months [1]. Even without surgery, epithelioid patients have the longest survival across all treatment modalities.

Sarcomatoid (10-15% of cases): Historically the most aggressive subtype, with stage III survival of approximately 6 to 8 months across all treatments. However, immunotherapy has fundamentally changed this picture. CheckMate 743 showed non-epithelioid patients achieved 12% 5-year survival with nivolumab/ipilimumab versus just 1% with chemotherapy (HR 0.48) [2]. This means sarcomatoid patients should almost always be offered immunotherapy as first-line treatment.

Biphasic (15-25% of cases): Contains both epithelioid and sarcomatoid elements. Prognosis depends on the ratio — more epithelioid features correlate with better outcomes. Biphasic patients are grouped with sarcomatoid as "non-epithelioid" in most trials and benefit from the same immunotherapy advantage.

The IASLC prognostic analysis confirmed that non-epithelioid histology carries a hazard ratio of 1.61, meaning roughly 61% higher risk of death compared to epithelioid at any given time point [9]. This is why confirming your exact cell type through expert pathology review is one of the most important early steps after diagnosis.

"I always tell patients: before we talk about treatment options, let us make absolutely sure the pathology is right. I have seen cases where a community pathologist called biphasic that turned out to be epithelioid on review at a specialized center. That reclassification changed the entire treatment strategy — and it changed the prognosis."

— David Foster, Director of Client Services, Danziger & De Llano

What Prognostic Factors Work in Your Favor?

Beyond cell type and stage, several factors are associated with longer survival in stage III pleural mesothelioma. Knowing which ones apply to you helps set realistic expectations and may influence treatment decisions.

Favorable prognostic factors:

• Epithelioid histology — The most consistent predictor of better outcomes across every analysis [9].
• Good performance status (ECOG 0-1) — Patients who are active and able to carry out most daily activities tolerate aggressive treatment better and live longer [9][13].
• N0 lymph node status — No lymph node involvement opens the door to surgical options and is associated with better survival within stage III [4][8].
• Treatment at a high-volume center — The IASLC data and multiple institutional series show that case volume and multidisciplinary tumor board involvement improve outcomes. Learn more about identifying the right center in our hospital and treatment center guide.
• Female gender — Women consistently show better mesothelioma survival across registries, though the reasons are not fully understood [9].
• Younger age at diagnosis — While mesothelioma is predominantly a disease of older adults, younger patients generally tolerate more aggressive treatment and have better baseline organ function.
• Low platelet count and normal hemoglobin — Laboratory values that indicate lower systemic inflammation correlate with better prognosis [9].

Unfavorable prognostic factors:

• Non-epithelioid histology (HR 1.61) [9]
• N2 lymph node involvement
• Poor performance status (ECOG 2+)
• Elevated platelet count and low hemoglobin
• Stage III-IV versus I-II (HR 1.49) [9]

What Does Conditional Survival Mean for Stage 3 Patients?

One of the most underappreciated findings in mesothelioma research is the concept of conditional survival. Initial survival statistics — the numbers you hear at diagnosis — describe the average outcome for all patients from the moment of diagnosis. But those averages become less relevant as you survive.

For pleural mesothelioma patients who survive 2 years past diagnosis, studies show they gain 5 to 8 additional years of life expectancy. This phenomenon occurs because the patients most likely to have rapid progression are no longer in the denominator. Each year of survival shifts the statistical curve in the patient's favor.

What this means practically: if you are diagnosed with stage III pleural mesothelioma and respond well to initial treatment, the prognosis at your 1-year mark is better than it was at diagnosis. At the 2-year mark, it improves further. The initial median survival number of 15 to 19 months represents the starting point, not the ceiling. If your spouse or family member is navigating this alongside you, our guide for spouses of stage 3 mesothelioma patients covers the caregiver perspective and practical next steps.

"Conditional survival is the data point I wish every newly diagnosed patient could internalize. The median survival statistic is a snapshot taken before you start treatment, before your body responds, before we know how the disease behaves in you specifically. For patients who make it past the first two years, the long-term outlook is dramatically better than what that initial number suggested."

— David Foster, Director of Client Services, Danziger & De Llano

How Should You Build a Treatment Decision Framework?

With 5 treatment paths available, the decision is not simple. The following framework, based on the 2025 ASCO guideline and current trial data, can help structure the conversation with your oncology team [4]:

Step 1: Confirm your exact substaging and cell type. Request a pathology review at a specialized center if your diagnosis was made at a community hospital. The distinction between T3 N0, T3 N1, and T1-3 N2 directly determines surgical eligibility.

Step 2: Determine surgical candidacy. If you have T1-3 N0 epithelioid disease, discuss surgery-based multimodal therapy with a thoracic surgeon experienced in mesothelioma [4]. The conversation should include whether pleurectomy/decortication (PD) is feasible — PD is associated with 7 months longer survival than extrapleural pneumonectomy [11]. Ask specifically about perioperative immunotherapy protocols, which have shown median OS of 28.6 months [7].

Step 3: If not surgical, determine immunotherapy eligibility. Non-epithelioid patients should almost always receive nivolumab/ipilimumab as first-line treatment given the HR of 0.48 [2]. Epithelioid patients may choose between nivolumab/ipilimumab and chemotherapy-immunotherapy combinations, weighing the higher response rate of chemo/pembro (52% ORR) against the stronger long-term survival signal of nivo/ipi [2][3].

Step 4: Explore clinical trials. Regardless of which standard treatment you pursue, ask whether a clinical trial might offer additional benefit. Trials such as eVOLVE-Meso (NCT06097728) and the CAR-T programs represent the next generation of treatment. Review our clinical trial pipeline guide for details on what is enrolling now.

Step 5: Engage palliative care from day one. Palliative care is not end-of-life care — it is symptom management alongside active treatment. Early palliative care integration improves quality of life and, in some studies, even improves survival [13].

What Should You Do in the First 2 Weeks After Diagnosis?

The period immediately following a stage 3 diagnosis is when the most impactful decisions get made. Here is a prioritized action list:

1. Get your pathology reviewed at a center that sees high volumes of mesothelioma cases. Cell type confirmation is the foundation of every treatment decision.
2. Request staging imaging — ideally a PET-CT and MRI of the chest — to define T descriptor and lymph node status precisely.
3. Seek evaluation at a specialized center. Even if you continue treatment locally, an initial evaluation at a high-volume center ensures you are not missing surgical candidacy or a relevant clinical trial. Use our guide to mesothelioma treatment centers to find one.
4. Ask about clinical trial eligibility. Trial slots are limited, and some close quickly. The earlier you inquire, the more options remain available.
5. Consult a mesothelioma attorney. Statutes of limitations vary by state and can be as short as 1 year from diagnosis. Asbestos trust funds hold over $30 billion, and the financial resources can offset treatment costs. Call 855-699-5441 for a free case evaluation.
6. Complete your emergency action checklist — the essential medical, legal, and financial steps that protect your rights and your family.

"Speed matters in the first two weeks, but precision matters more. I would rather see a patient take 10 days to get a proper second opinion at a specialized center than start treatment on day 3 based on incomplete staging. The right treatment plan at the right center is worth more than starting a week earlier at a facility that sees two mesothelioma cases a year."

— David Foster, Director of Client Services, Danziger & De Llano

Why Do Real-World Outcomes Differ from Clinical Trial Data?

One important caveat with all of the survival data in this article: patients treated in real-world settings typically experience outcomes 3 to 5 months shorter than published clinical trial results [13]. This gap exists for several reasons:

• Trial eligibility filters out sicker patients. Clinical trials require adequate organ function, reasonable performance status, and absence of certain comorbidities. The trial population is healthier on average than the general mesothelioma population.
• Trial sites are specialized centers. Patients treated at NCI-designated cancer centers with dedicated mesothelioma programs receive the benefit of multidisciplinary tumor boards, experienced surgeons, and structured follow-up protocols.
• Adherence is higher in trials. Treatment delays, dose reductions, and early discontinuation are less common in trial settings where protocol adherence is closely monitored.
• Supportive care is standardized. Trials mandate specific supportive care protocols (anti-emetics, growth factors, surveillance imaging intervals) that may not be consistently applied in community practice.

This does not mean trial data is irrelevant. Rather, it means that if you can access treatment at a specialized center — ideally within a clinical trial — your outcomes are likely to be closer to the published data. The gap between trial and real-world outcomes is itself an argument for seeking specialized care.

What Are the Most Common Questions About Stage 3 Mesothelioma?

What is the median survival for stage 3 pleural mesothelioma?

Stage III pleural mesothelioma median survival ranges from 15.5 months with chemotherapy alone to 18.9 months with surgery-based multimodal therapy, according to a 2023 National Cancer Database analysis [1]. Epithelioid cell type patients who undergo surgery have a median survival of approximately 22 months. These figures predate widespread immunotherapy use, so outcomes in 2026 may be somewhat better for patients receiving nivolumab plus ipilimumab.

Can stage 3 mesothelioma be treated with surgery?

Some stage 3 patients are surgical candidates, but eligibility depends on specific substaging and cell type. The 2025 ASCO guideline recommends surgery only for T1-3 N0 epithelioid disease [4]. Patients with N1-N2 lymph node involvement are generally directed toward systemic therapy. When surgery is offered, pleurectomy/decortication (PD) is preferred over extrapleural pneumonectomy, with a meta-analysis showing PD is associated with 7 months longer survival [11].

What is the 5-year survival rate for stage 3 mesothelioma?

The overall 5-year survival rate for regional-stage (approximately stage II-III) pleural mesothelioma is about 4% based on SEER data [10]. However, CheckMate 743 5-year data show that immunotherapy with nivolumab plus ipilimumab achieves 14% 5-year overall survival versus 6% with chemotherapy [2]. For non-epithelioid subtypes, the gap is even wider: 12% with immunotherapy versus 1% with chemotherapy.

Is immunotherapy better than chemotherapy for stage 3 mesothelioma?

For non-epithelioid subtypes (sarcomatoid and biphasic), immunotherapy with nivolumab plus ipilimumab is clearly superior, with a hazard ratio of 0.48 and 12% versus 1% 5-year survival [2]. For epithelioid subtypes, the benefit is more nuanced. Some oncologists still prefer chemotherapy first for epithelioid patients, potentially followed by immunotherapy at progression. The IND.227 trial also showed that adding pembrolizumab to chemotherapy improved response rates to 52% [3].

What clinical trials are available for stage 3 mesothelioma in 2026?

Several major trials are enrolling stage 3 patients in 2026. eVOLVE-Meso (NCT06097728) is a Phase III trial testing volrustomig, a bispecific antibody, in 825 patients. Five CAR-T cell trials are open, with Memorial Sloan Kettering reporting 72% objective response rates using an intrapleural delivery approach. Perioperative immunotherapy trials combining nivolumab with or without ipilimumab around surgery have shown median OS of 28.6 months [7].

What factors determine prognosis in stage 3 mesothelioma?

The strongest prognostic factors are cell type (epithelioid versus non-epithelioid, HR 1.61), stage (III-IV versus I-II, HR 1.49), performance status, and treatment center expertise [9]. Epithelioid stage III patients treated with surgery at specialized centers have median survival around 22 months, while sarcomatoid patients across all treatments survive approximately 6 to 8 months. Age, gender, and nutritional status also influence outcomes.

What does conditional survival mean for mesothelioma patients?

Conditional survival measures the probability of surviving additional years given that a patient has already survived a certain period. For pleural mesothelioma patients who survive 2 years past diagnosis, studies show they gain 5 to 8 additional years of life expectancy. This means the prognosis improves substantially for patients who respond well to initial treatment, and survival estimates at diagnosis become less relevant over time.

What Should Your Next Step Be?

A stage 3 pleural mesothelioma diagnosis demands fast, informed action. Whether you are exploring surgical options, immunotherapy, or clinical trials, the decisions you make in the next 2 weeks shape your treatment trajectory. For additional resources, visit our stage 3 mesothelioma guide, explore legal options for mesothelioma patients, or learn about choosing a mesothelioma lawyer. Start with our free mesothelioma case evaluation to understand your legal options and access financial resources for treatment. You can also speak directly with our team at 855-699-5441 — we have helped families navigate this diagnosis for over 18 years, and the consultation is free and confidential.

References

1. [1] Bou-Samra P, et al. Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: A review of the National Cancer Database. Cancer Medicine. 2023. PMC PMC10278474. PubMed
2. [2] Scherpereel A, et al. First-Line Nivolumab Plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743): 5-Year Update. J Clin Oncol. 2026;44(9):742-749. PubMed
3. [3] Chu Q, et al. Pembrolizumab Plus Chemotherapy Versus Chemotherapy in Untreated Advanced Pleural Mesothelioma: IND.227. J Thorac Oncol. 2023;18(6):813-819. PubMed
4. [4] Malignant Pleural Mesothelioma: ASCO Guideline. Journal of Clinical Oncology. 2025. DOI: 10.1200/JCO-24-02425. ASCO Pubs
5. [5] Szlosarek PW, et al. Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial. JAMA Oncology. 2024. PubMed
6. [6] Lim E, et al. Extended Pleurectomy Decortication and Chemotherapy Versus Chemotherapy Alone for Pleural Mesothelioma (MARS 2). Lancet Respir Med. 2024;12(6):457-466. PubMed
7. [7] Perioperative Nivolumab or Nivolumab Plus Ipilimumab in Resectable Diffuse Pleural Mesothelioma: A Phase 2 Trial. Nat Med. 2025;31:4097-4108. PubMed
8. [8] Rusch VW, et al. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2016;11(12):2089-2099. PubMed
9. [9] Wolf AS, et al. Prognostic Factors for Survival in Malignant Pleural Mesothelioma — An Analysis of the IASLC Mesothelioma Database. Journal of Thoracic Oncology. 2023. PubMed
10. [10] SEER Cancer Statistics Review: Mesothelioma. National Cancer Institute SEER Program. SEER
11. [11] Brivio A, et al. Systematic Review and Meta-Analysis of Pleurectomy/Decortication versus Extrapleural Pneumonectomy in the Treatment of Malignant Pleural Mesothelioma. J Clin Med. 2022;11(19):5544. PubMed
12. [12] Ceresoli GL, et al. TTFields With Chemotherapy for Malignant Pleural Mesothelioma (STELLAR). The Lancet Oncology. 2019. PubMed
13. [13] Malignant Pleural Mesothelioma Treatment (PDQ) — Health Professional Version. National Cancer Institute. NCI
14. [14] Understanding Your Diagnosis. WikiMesothelioma. WikiMesothelioma
15. [15] Mesothelioma Treatment Centers. WikiMesothelioma. WikiMesothelioma
16. [16] Emergency Action Checklist. WikiMesothelioma. WikiMesothelioma